Prostate tumors are initially dependent on androgens for growth, but the majority of patients treated with antiandrogen therapy progress to androgen-independence characterized by resistance to such treatment. This study investigates a novel role for filamin A (FlnA), a 280 kDa cytoskeletal protein (consisting of an actin-binding domain (ABD) followed by 24 sequential repeats), in androgen-independent (AI) growth. Full-length FlnA is cleaved to 170 kDa (ABD þ FlnA1-15) and 110 kDa fragments (FlnA16-24); the latter is further cleaved to a 90 kDa fragment (repeats 16-23) capable of nuclear translocation and androgen receptor (AR) binding. Here, we demonstrate that in androgen-dependent LNCaP prostate cancer cells, the cleaved 90 kDa fragment is localized to the nucleus, whereas in its AI subline C4-2, FlnA failed to cleave and remained cytoplasmic. Transfection of FlnA16-24 cDNA in C4-2 cells restored expression and nuclear localization of 90 kDa FlnA. Unlike LNCaP, C4-2 cells proliferate in androgenreduced medium and in the presence of the AR-antagonist Casodex. They also exhibit increased Akt phosphorylation compared to LNCaP, which may contribute to their AI phenotype. Nuclear expression of 90 kDa FlnA in C4-2 cells decreased Akt phosphorylation, prevented proliferation in androgen-reduced medium and restored Casodex sensitivity. This effect was inhibited by constitutive activation of Akt indicating that FlnA restored Casodex sensitivity in C4-2 cells by decreasing Akt phosphorylation. In addition, FlnA-specific siRNA which depleted FlnA levels, but not control siRNA, induced resistance to Casodex in LNCaP cells. Our results demonstrate that expression of nuclear FlnA is necessary for androgen dependence in these cells.
Introduction
Most prostate tumors are initially dependent on androgens for growth and thus responsive to androgen ablation. However, the majority of patients treated with hormonal therapy ultimately progress to an androgeninsensitive or hormone refractory state (Isaacs, 2000) . The continuing survival and proliferation of these androgen-independent prostate cancer (AIPC) cells eventually prove fatal to the patient (Isaacs, 2000) . Currently, there is no established therapy that cures hormone refractory disease.
Filamins are a family of cytoskeletal proteinsfilamins A and B, but not C, are expressed in nonmuscle cells. Filamin A (FlnA) is a 280 kDa protein consisting of an N-terminal actin-binding domain (ABD) and a rodlike domain of 24 repeats (each 96-amino acid long), interrupted by 30-amino-acid flexible loops, H1 (between 15 and 16) and H2 (between 23 and 24) (Gorlin et al., 1990; van der Flier and Sonnenberg, 2001) . Filamins are essential for mammalian cell locomotion and act as interfaces for proteinprotein interaction (van der Flier and Sonnenberg, 2001) . Loss of FlnA results in neuronal disorders, such as periventricular heterotopia (Thomas et al., 1996; van der Flier and Sonnenberg, 2001; Robertson et al., 2003) . H1 and H2 can be cleaved by calpains and caspases (Gorlin et al., 1990; Browne et al., 2000) . Cleavage at H1 occurs between aa 1761 and 1762 and results in a 170 kDa fragment consisting of the ABD and repeats 1-15 (FlnA1-15) and a 110 kDa protein consisting of repeats [16] [17] [18] [19] [20] [21] [22] [23] [24] , which is further cleaved at H2 to yield a 90 kDa fragment (Gorlin et al., 1990; van der Flier and Sonnenberg, 2001) . Alternatively, spliced variants of FlnA lacking the H1 domain, which therefore is not capable of being cleaved, has been reported earlier (Barry et al., 1993) , but the H2 domain is expressed universally (van der Flier and Sonnenberg, 2001) .
The genomic effects of androgens are mediated by their binding to the androgen receptor (AR), a transcription factor with many known targets including prostate-specific antigen (PSA), a serum biomarker for prostate cancer (Culig et al., 2003) . FlnA has been identified as an AR-binding protein (Ozanne et al., 2000; Loy et al., 2003) . The 90 kDa FlnA fragment interacted with the AR and translocated to the nucleus (Ozanne et al., 2000) , resulting in repression of AR transcriptional activity (Loy et al., 2003) . FlnA binds to the AR hinge region (Loy et al., 2003) , although the area on FlnA for AR interaction has been found to be on repeats 18-19 (Ozanne et al., 2000) . These reports suggest that FlnA might be involved in prostate tumor biology. Indeed, a role for FlnA has been identified in prostate-specific membrane antigen enzymatic activity in prostate tumor cells (Anilkumar et al., 2003; Ghosh et al., 2005a) .
One of the hallmarks of androgen-independence is failure of tumors to regress on anti-androgen therapy. The pharmaceutical drug bicalutamide (Casodex) is commonly used as an anti-androgen to treat recurrent prostate cancer. Casodex is a competitive inhibitor of the AR and prevents androgen binding to the AR by blocking its binding sites (Masiello et al., 2002) . As a result, androgen-dependent cells are growth-inhibited by Casodex, but AI cells are refractory to this treatment. In this study, we show that the presence of the 90 kDa FlnA fragment in the nucleus induces sensitivity to Casodex in AI C4-2 cells, a subline of androgendependent LNCaP cells. Our data suggest that expression of FlnA in the nucleus maintains Casodex sensitivity of prostate cancer cells, and therefore may be of therapeutic value in the future.
Results
The 90 kDa fragment translocates to the nucleus of androgen-dependent, but not androgen-independent prostate tumor cells We compared the expression of FlnA in various prostate cancer cell lines (Figure 1a ). High levels of FlnA were observed in all cell lines except 22Rv1, an AI cell line derived from androgen-dependent CWR22 prostate tumors ( Figure 1a, top panel) . Expression of the 90 kDa band was high in AR-negative PC-3 and DU-145 cells compared to LNCaP and was further decreased in AI clones of LNCaP (LNAI) and C4-2 cells, AI cell lines derived from LNCaP (Wu et al., 1994; Shi et al., 2004) -suggesting insufficient cleavage of the full-length protein ( Figure 1a , second panel). Three cell lines with varying expression of the 90 kDa fragment were chosen for further investigation (LNCaP, C4-2 and PC-3) and were subjected to subcellular fractionation. The 280 kDa FlnA band was found to be expressed primarily in the cytoplasmic fraction in all cell lines investigated (Figure 1b, upper panel) . LNCaP cells, but not C4-2, showed substantial expression of the 90 kDa band both in the nucleus and the cytoplasm (Figure 1a and b) . However, the AR in both LNCaP and C4-2 was primarily nuclear (Figure 1b Figure 2) . In addition, androgen-dependent CWR22 tumors, but not AI tumors obtained from implants of 22Rv1, expressed nuclear FlnA (Supplementary Figure  2) , thus reinforcing the observations of nuclear localization in androgen-dependent tumors.
Androgen-independent cells are characterized by a resistance to growth arrest by the anti-androgen Casodex We compared the growth characteristics of LNCaP and C4-2 cells. Both cell lines exhibited higher proliferation rates in complete medium (containing fetal bovine serum (FBS)) compared to that in charcoalstripped serum (CSS), containing reduced hormone levels ( Figure androgen dependence, the effect of these plasmids on Casodex sensitivity was tested. C4-2 cells expressing FlnA16-24 but not FlnA1-15 or the empty vector, were growth inhibited by 10 mM Casodex (Figure 4c ). These experiments were repeated in LNAI cells with similar results (Figure 4d ). However, FlnA 16-24 failed to have an effect in AR null PC-3 cells or in 22Rv1 cells, which express a constitutively active AR (not shown). LNCaP cells have a mutation in the AR (T877A), which is also present in C4-2 cells (Hsieh et al., 1993) . Another antiandrogen, hydroxyflutamide, acts as an agonist in LNCaP cells and its androgen-independent sublines due to this mutation (Culig et al., 1999) . Nuclear expression of FlnA 16-24 failed to override the effects of this mutation (Supplementary Figure 4) . These results indicate that the effects of FlnA are secondary to that of the AR and are specific to cells where the androgenregulated pathway was intact. Kip1 (lowermost panel).
Nuclear 90 kDa filamin A promotes Casodex-induced growth inhibition Y Wang et al growth inhibited by 10 mM Casodex, but those transfected with siRNA1P or siRNA2 were not (Figure 5c ). After the 3rd day the siRNA lost effectiveness (Figure 5c , inset), and by day 5, Casodex started to inhibit growth in all three groups of cells indicating that FlnA's effects were reversible. These results demonstrate that the presence of FlnA is necessary for Casodexinduced growth inhibition in LNCaP cells.
FlnA-induced Casodex sensitivity may be mediated by decreased Akt phosphorylation
We previously showed that Akt and p70S6 kinase, but not ERK, regulated cell growth in both LNCaP and C4-2 cells (Ghosh et al., 2005b) . C4-2 cells expressed increased phosphorylation (activation) of Akt and p70S6 kinase compared to LNCaP (Figure 6a , left panels), a phenomenon that was previously shown to be related to the development of androgen independence (Graff et al., 2000; Ghosh et al., 2005b) . AI growth of C4-2 cells is, at least partly, due to activation of nonandrogen-regulated growth stimulated by increased Akt phosphorylation (Ghosh et al., 2005b and unpublished observations) . Hence, we investigated whether FlnA affected the activation of these kinases. C4 16-24 cells showed decreased Akt and p70S6 kinase phosphorylation (Figure 6a , right panels), but not ERK (not shown), compared to vector transfected C4-2 cells. As before, transfection of FlnA 16-24 promoted Casodex-induced growth inhibition, but cotransfection of constitutively active Akt (myr-Akt) prevented this effect (Figure 6b ), suggesting that FlnA 16-24's effects are mediated by the decrease it causes in Akt phosphorylation. To investigate why constitutive Akt phosphorylation prevented FlnA16-24's effects, LNCaP cells were transfected with plasmids expressing dominant negative (dn-Akt) or constitutively active Akt (myr-Akt). We previously reported the successful expression of these plasmids in these cells (Ghosh et al., 2005b) . shows FlnA/AR binding in LNCaP cells expressing wild type (wt) and dn-Akt, which was inhibited by the expression of myr-Akt, suggesting that increased Akt activation maintained Casodex resistance by preventing FlnA-AR interactions. We therefore asked why Akt would prevent FlnA-AR interactions.
Phosphorylation of FlnA at Ser 2152 was shown to make this protein resistant to cleavage by calpains at the H1 domain (Gorlin et al., 1990; Jay et al., 2000; van der Flier and Sonnenberg, 2001) . Figure 6d shows that FlnA phosphorylation of the 280 kDa band at Ser2152 was increased in C4-2 cells compared to LNCaP. Next, we investigated whether Akt regulated FlnA phosphorylation at Ser 2152. This phosphorylation was inhibited by the PI3 K inhibitor LY294002, which inhibits Akt and p70S6 kinase and rapamycin, which inhibits p70S6 kinase, but not by PD98059, an inhibitor of ERK1/2 (Figure 6e ). Effectiveness of these drugs at the concentrations used have been demonstrated in C4-2 cells earlier (Ghosh et al., 2005b) . LY294002 did not affect the levels of 280 kDa FlnA, but caused the 90 kDa FlnA band to reappear in C4-2 cells. These results suggest that Akt phosphorylates FlnA at Ser 2152, which prevents FlnA cleavage to the 90 kDa band. This retains FlnA in the cytoplasm and prevents its interaction with the AR.
Discussion
Previous studies showed that FlnA binds to the AR and colocalizes to the nucleus (Ozanne et al., 2000) , resulting in suppression of AR transcriptional activity (Loy et al., 2003) . However, the functional significance of FlnA nuclear localization had not been investigated previously. In this paper, we make the novel observation that androgen-dependent LNCaP cells, but not AI cell lines, express nuclear FlnA and that the presence of FlnA in the nucleus promotes androgen dependence. Further, we provide evidence that this effect of FlnA may be mediated by Akt phosphorylation. FlnA-induced androgen dependence can, however, be achieved only in cells that express a ligand-activated AR. This protein failed to have an effect in AR-negative PC-3 cells as well as in 22Rv1 cells, which express a constitutively active and truncated AR lacking part of the ligand-binding domain (Tepper et al., 2002) . Nuclear 90 kDa filamin A promotes Casodex-induced growth inhibition Y Wang et al
Nuclear entry of FlnA is thus a two-step process involving (1) cleavage of the full-length protein and (2) translocation of the cleaved product into the nucleus. Molecular mechanisms necessary for nuclear translocation of FlnA is intact in C4-2 cells and failure to cleave is caused by increased phosphorylation at Ser 2152, which renders the protein resistant to cleavage at H1 (Gorlin et al., 1990) . The Ser 2152 site on FlnA is known to be a substrate for a number of kinases -including, PKA (Jay et al., 2000 (Jay et al., , 2004 , p90 RSK (Woo et al., 2004) and PKCa´ (Tigges et al., 2003) . We show here that the PI3K/Akt pathway regulates the phosphorylation of FlnA in C4-2 cells. Although filamin C was identified as a target of Akt-induced phosphorylation (Murray et al., 2004) , no such site has been found on FlnA (Woo et al., 2004) . Therefore, it is likely that Akt's effect on FlnA phosphorylation is indirect and may include secondary activation of known kinases.
At the present time, the cause of nuclear exclusion of the 90 kDa FlnA in PC-3 cells is not known. An elegant study in an FlnA-deficient melanoma cell line (Ozanne et al., 2000) show that expression of FlnA is necessary for AR nuclear translocation in those cells. However, this does not seem to be the case in prostate cancer cells, as C4-2 cells expressed nuclear AR, despite a lack of nuclear FlnA (Figure 1b) . Further, loss of FlnA expression in LNCaP cells, by treatment with FlnA siRNA, did not affect nuclear localization of the AR (Supplementary Figure 5) . These results show that nuclear expression of FlnA is not necessary for AR nuclear translocation in prostate cancer cells. As FlnA is a scaffolding protein (van der Flier and Sonnenberg, 2001) , perhaps in melanoma cells, but not in prostate cancer cells, a critical AR coregulator requires FlnA binding before AR nuclear translocation. Translocation to the nucleus requires a nuclear localization signal (Dingwall and Laskey, 1991) , and no such signal has been reported on FlnA. Hence, it is likely that FlnA translocates to the nucleus as a result of binding to the AR, which does have a nuclear localization signal (Jenster et al., 1992) . Therefore, PC-3 cells may lack FlnA nuclear localization because of the absence of a functional AR to bind FlnA.
Surprisingly, transfection of wtAR in PC-3 cells (PC-3/AR) decreased overall FlnA expression (Supplementary Figure 6 ), and cotransfection of wtAR and FlnA 16-24 in these cells were lethal (not shown). These results suggest that AR transcriptional activity inhibited FlnA expression and also that, despite AR expression, these cells remained AI. In support of these observations, PC-3/AR cells survived only in medium with charcoalstripped serum and physiological levels of DHT (as in medium with FBS) resulted in apoptosis and inhibition of cell growth (Heisler et al., 1997) , and in other words, remained AI. Further studies are needed to elucidate the mechanism by which these effects occur in PC-3 cells. The question then is, how the 90 kDa FlnA fragment, once introduced into the nucleus of C4-2 cells, renders the cells sensitive to Casodex-induced growth inhibition. Casodex, either as a combination or monotherapy, is commonly used to treat patients with recurrent prostate cancer. Resistance to this drug is considered an indicator of androgen independence in humans. Prolonged culture of LNCaP cells in androgen-reduced medium has been shown to give rise to a subline that was growthstimulated by Casodex (Culig et al., 1999) . C4-2 cells may not be stimulated by Casodex, but they are not inhibited either. Multiple causes are attributed to Casodex resistance of prostate cancer cells, including AR mutations (Hara et al., 2003) . However, no additional mutations in C4-2 cells were observed other than the T877A mutation observed in LNCaP cells (unpublished observations). Despite this mutation, LNCaP cells remained androgen-dependent, so this mutation obviously did not play a role in the emergence of androgen independence in C4-2 cells. Previous studies showed that FlnA binds to and represses AR transcriptional activity (Loy et al., 2003) . However, simply decreasing AR transcriptional activity is an unlikely mechanism for converting AI cells to androgen-dependent, as Casodex inhibits AR-regulated PSA expression in C4-2 cells (Figure 2 ), but did not make them androgen-dependent.
We earlier showed an important role for Akt in prostate cancer (Malik et al., 2002; Ghosh et al., 2003 Ghosh et al., , 2005b Kreisberg et al., 2004) . Akt and p70S6 kinase, but not ERK, regulated prostate cancer cell proliferation (Ghosh et al., 2005b) . Others (Graff et al., 2000) showed that increased Akt phosphorylation resulted in the development of androgen independence. Our previous results also suggested that increased Akt phosphorylation promoted AI growth of C4-2 cells (Ghosh et al., 2005b) , possibly by activating additional signal transduction pathways. Increased Akt activation has been shown to stimulate ligand-independent AR activation as well, which would contribute to AI growth (Wen et al., 2000; Manin et al., 2002) . Feldman and Feldman (2001) had suggested the presence of five alternate pathways in the development of androgen independence including 'bypass' pathways. Akt may activate such bypass pathways resulting in AI proliferation and survival. Here, we show that transfection of FlnA 16-24 resulted in decreased Akt and p70S6 kinase phosphorylation, by a yet-unknown mechanism. This would result in suppression of proliferative signals resulting in AI growth, thereby enabling the appearance of androgen-dependent pathways.
In conclusion, we show that androgen-dependent LNCaP prostate cancer cells express nuclear FlnA, whereas in AI cell lines, FlnA is mostly cytoplasmic. Transfection of FlnA16-24 cDNA restored nuclear localization of the 90 kDa fragment in these cells and restored an androgen-dependent phenotype, whereas downregulation of FlnA by FlnA-specific siRNA induced resistance to Casodex in LNCaP cells. FlnA's effects on androgen dependence may be mediated by a decrease in Akt phosphorylation previously shown to be associated with the development of androgen independence in AI sublines of LNCaP cells. In turn, Akt promotes decreased FlnA cleavage by phosphorylation of FlnA at Ser 2152 (see Figure 7) . These results suggest that expression of nuclear FlnA may be a future target of therapy for AIPC not involving AR mutations.
Materials and methods
Technical details regarding various methods are provided in Supplementary Information. 
